Snus: Difference between revisions
Richardpruen (talk | contribs) Added note on reason for refigereation |
Richardpruen (talk | contribs) Changed to a generic image - no branding. Example of appearance only |
||
| (5 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
__TOC__ | __TOC__ | ||
[[File: | [[File:Snus.jpg|alt=Picture of a can of Snus as example of the product|thumb|Example of Snus]] | ||
== Description == | == Description == | ||
| Line 21: | Line 21: | ||
* Snus is considered by scientists to be 95%, and possibly closer to 99%, less risky than smoking | * Snus is considered by scientists to be 95%, and possibly closer to 99%, less risky than smoking | ||
* Snus poses no respiratory risk. | * Snus poses no respiratory risk. It cannot cause respiratory diseases, predominantly lung cancer, chronic obstructive pulmonary disease tobacco smoke does, nothing is inhaled. | ||
* Low risk oral nicotine product. | * Low risk oral nicotine product. | ||
* Highly effective way of quitting cigarettes. | * Highly effective way of quitting cigarettes. | ||
| Line 31: | Line 31: | ||
* Snus may cause irritation of the oral mucosa and a stinging/tingling sensation, however 'Sting free Snus' is one approach to help solve this. The other is to place the pouches in different locations each time. Note there is '''no link to disease or cancer,''' merely discomfort at worst. | * Snus may cause irritation of the oral mucosa and a stinging/tingling sensation, however 'Sting free Snus' is one approach to help solve this. The other is to place the pouches in different locations each time. Note there is '''no link to disease or cancer,''' merely discomfort at worst. | ||
=== Is | === Is Snus an appropriate and acceptable harm reduction product? === | ||
Snus fulfils the criteria for a tobacco harm reduction product. It is a low risk nicotine product and delivers acceptable doses to those who use it. In countries in which it is allowed it is popular and has contributed to declines in smoking and smoking related diseases. | Snus fulfils the criteria for a tobacco harm reduction product. It is a low risk nicotine product and delivers acceptable doses to those who use it. In countries in which it is allowed it is popular and has contributed to declines in smoking and smoking related diseases. | ||
[[File:Sweden thr.jpg|none|thumb|Nicotine use is around the EU average, but safer product Snus save lives. Proof of harm reduction. ]] | |||
=== The human cost of the ban on snus === | === The human cost of the ban on snus === | ||
| Line 42: | Line 43: | ||
=== Africa === | === Africa === | ||
Snus may be banned in some locations, legal in others. It's use is not common, other more harmful oral tobacco is used more often. | Snus may be banned in some locations, legal in others. It's use is not common, other more harmful oral tobacco [[SLT|(see SLT)]] is used more often. | ||
=== Europe === | === Europe === | ||
| Line 76: | Line 77: | ||
== Studies general information == | == Studies general information == | ||
==== 2024:[https://link.springer.com/epdf/10.1186/s12954-024-01095-7?sharing_token=_1R3Pf6IlmYuu1rCO8WKR2_BpE1tBhCbnbw3BuzI2ROn4zJn13QApxXLzZ1Nm2EMUkgR9kBcTUj-17Nn5d2sQs8mLy3R96OBBGptbTCRJIWB4pPY-WWLKJ0DqqKOq-LBdg_MBr5Q2Y15L5xIyeK8sAjjshzb6jigkC1RlZKharE%3D If there had been no snus in Sweden: the impact of snus on mortality attributable to smoking] ==== | |||
* It is made up by comparisons between observed Swedish data and two scenarios without snus: a group of comparable countries, and, a hypothetical Sweden with no snus use. | |||
* Both comparisons suggest that around 3000 lives per year have been saved by the use of snus in Sweden. | |||
* The potential of snus to reduce smoking-attributable mortality can be elucidated by comparing Swedish data on smoking-attributable mortality with corresponding data from comparable countries with virtually no snus. Switzerland and most EU countries outside Sweden | |||
==== '''2022:''' [https://onlinelibrary.wiley.com/doi/10.1111/eos.12885 The effect of a non-tobacco-based nicotine pouch on mucosal lesions caused by Swedish smokeless tobacco (snus)] (Sara Alizadehgharib, Anna Lehrkinder, Ali Alshabeeb, Anna-Karin Östberg, Peter Lingström) ==== | ==== '''2022:''' [https://onlinelibrary.wiley.com/doi/10.1111/eos.12885 The effect of a non-tobacco-based nicotine pouch on mucosal lesions caused by Swedish smokeless tobacco (snus)] (Sara Alizadehgharib, Anna Lehrkinder, Ali Alshabeeb, Anna-Karin Östberg, Peter Lingström) ==== | ||
| Line 187: | Line 194: | ||
===2015: [https://www.sciencedirect.com/science/article/abs/pii/S0955395914002175 The incentives created by a harm reduction approach to smoking cessation: Snus and smoking in Sweden and Finland]=== | ===2015: [https://www.sciencedirect.com/science/article/abs/pii/S0955395914002175 The incentives created by a harm reduction approach to smoking cessation: Snus and smoking in Sweden and Finland]=== | ||
[[ | [[Category:THR product]] | ||
[[ | [[Category:Smoking cessation]] | ||